Psilocybin (Psilocybe spp.) is being tested in at least 6 registered clinical trials for anorexia nervosa, binge-eating disorder, and body dysmorphic disorder, with therapeutic doses typically 20–30 mg in a single session combined with psychotherapy. Across early trials and related psychiatric studies, one or two sessions at 25 mg have produced large, durable shifts in cognitive rigidity, fear learning, and self-concept that persist 3–6 months after dosing, the same core circuits that drive compulsive restriction, binge cycles, and body-image fixation.